Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025

Company Overview - Curis, Inc. is a biotechnology company focused on the development of emavusertib (CA-4948), an orally available small molecule IRAK4 inhibitor [3] - Emavusertib is currently being evaluated in multiple clinical studies, including the Phase 1/2 TakeAim Lymphoma study for patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and the Phase 1/2 TakeAim Leukemia study for patients with relapsed/refractory acute myeloid leukemia (AML) [3] - The drug has received Orphan Drug Designation from the U.S. FDA for the treatment of PCNSL, AML, and MDS, as well as from the European Commission for PCNSL [3] Upcoming Financial Results - Curis will report its first quarter 2025 financial and operating results on May 6, 2025, at 8:00 a.m. ET [1] - Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET [1][2] Collaboration and Licensing - Curis has an exclusive license to emavusertib through a collaboration with Aurigene established in 2015 [3] - The company licensed its rights to Erivedge® to Genentech, a member of the Roche Group, for the treatment of advanced basal cell carcinoma [3]